MARKET

LEGN

LEGN

Legend Biotech Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

54.14
-0.90
-1.64%
Closed 16:00 11/26 EST
OPEN
54.95
PREV CLOSE
55.04
HIGH
57.00
LOW
53.93
VOLUME
604.24K
TURNOVER
--
52 WEEK HIGH
58.00
52 WEEK LOW
23.41
MARKET CAP
7.83B
P/E (TTM)
-21.5251
1D
5D
1M
3M
1Y
5Y
Baker Bros. Advisors Lp Buys Ascendis Pharma A/S, Pacific Biosciences of California Inc, ...
GuruFocus News · 11/16 22:38
Legend Biotech EPS misses by $0.08, beats on revenue
Legend Biotech (NASDAQ:LEGN): Q3 GAAP EPS of -$0.43 misses by $0.08. Revenue of $16.82M (+43.3% Y/Y) beats by $8.99M. Shares +5.88% PM. Press Release
Seekingalpha · 11/16 13:50
Legend Biotech Q3 EPS $(0.43) Down From $(0.25) YoY, Sales $16.90M Up From $11.75M YoY
Legend Biotech (NASDAQ:LEGN) reported quarterly losses of $(0.43) per share. This is a 72 percent decrease over losses of $(0.25) per share from the same period last year. The company reported $16.90 million in sales
Benzinga · 11/16 13:31
Consonance Capital Management LP Buys Surrozen Inc, ARYA Sciences Acquisition Corp V, Olink ...
GuruFocus News · 11/15 16:38
Estimating The Intrinsic Value Of Legend Biotech Corporation (NASDAQ:LEGN)
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Legend Biotech...
Simply Wall St. · 11/05 14:27
BRIEF-Legend Biotech Showcases Updated and New Data from Comprehensive BCMA CAR-T, Cilta-Cel, Program and First Preclinical Results for Tri-specific CAR-T at 2021 ASH
reuters.com · 11/04 13:12
Legend Biotech Announces Extension of PDUFA Date for Cilta-Cel
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today announced that the U.S. Food and Drug Administration has extended the Prescription Drug...
Business Wire · 11/01 20:00
Hedge Funds Are Coming Back To Legend Biotech Corporation (LEGN)
In this article we will analyze whether Legend Biotech Corporation (NASDAQ:LEGN) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There’s no better way to get these firms’ immense...
Insider Monkey · 10/29 15:20
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LEGN. Analyze the recent business situations of Legend Biotech Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
60.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average LEGN stock price target is 63.60 with a high estimate of 71.00 and a low estimate of 51.00.
High71.00
Average63.60
Low51.00
Current 54.14
EPS
Actual
Estimate
-0.34-0.26-0.17-0.09
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 115
Institutional Holdings: 41.28M
% Owned: 28.54%
Shares Outstanding: 144.63M
TypeInstitutionsShares
Increased
34
14.23M
New
19
2.86M
Decreased
17
1.34M
Sold Out
16
3.44M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.30%
Pharmaceuticals & Medical Research
+0.44%
Key Executives
Non-Executive Chairman/Independent Director
Ye Wang
Chief Executive Officer/Chief Financial Officer
Huang Ying
Senior Vice President
Meeta Chatterjee
Vice President - Finance
Lori Macomber
Director
Li Zhu
Independent Director
Patrick Casey
Independent Director
Xiaohui Ji
Independent Director
Corazon Sanders
Independent Director
Wai Man Yau
No Data
About LEGN
Legend Biotech Corporation. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, LCAR- B38M (cilta-cel), is an autologous CAR-T cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in a number of hematologic malignancies, including multiple myeloma (MM). The Company have a portfolio of earlier-stage autologous product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), Acute Myeloid Leukemia (AML), and T cell Lymphoma (TCL). The Company is also developing allogeneic CAR-T product candidates targeting CD20 for the treatment of NHL. It also has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases.

Webull offers kinds of Legend Biotech Corp stock information, including NASDAQ:LEGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LEGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LEGN stock methods without spending real money on the virtual paper trading platform.